News & Events about Bioxcel Therapeutics.
BioXcel Therapeutics, Inc. (NASDAQ:BTAI Get Rating) insider Frank Yocca sold 50,000 shares of the businesss stock in a transaction on Friday, January 20th. The stock was sold at an average price of $30.00, for a total value of $1,500,000.00. Following the transaction, the insider now ...
BioXcel Therapeutics, Inc. (NASDAQ:BTAI Get Rating) insider Frank Yocca sold 50,000 shares of the businesss stock in a transaction on Friday, January 20th. The stock was sold at an average price of $30.00, for a total value of $1,500,000.00. Following the transaction, the insider now directly owns 8...
NEW HAVEN, Conn., Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel ...
BioXcel Therapeutics, Inc. (NASDAQ:BTAI Get Rating) CEO Vimal Mehta sold 30,000 shares of the companys stock in a transaction that occurred on Friday, December 16th. The stock was sold at an average price of $19.44, for a total transaction of $583,200.00. Following the sale, the chief...
BioXcel Therapeutics, Inc. (NASDAQ:BTAI Get Rating) CEO Vimal Mehta sold 30,000 shares of the companys stock in a transaction that occurred on Friday, December 16th. The stock was sold at an average price of $19.44, for a total transaction of $583,200.00. Following the sale, the chief executive ...